SN BioScience Inc

We are clinical stage (late Phase 1) nano-DDS oncology company.

[ SN-38 Nanoparticle update ]
(1) IND approved by both US FDA and S.Korea
(2) On-going 'Phase I' in S.Korea with SNB-101 manufactured in GMP facility(NCT04640480)
(3) Promising efficacy in a small cell lung cancer patients (PR over than 10 months)
(4) Promising safety more than 4 folds MTD compared with equivalent dose of Irinotecan in patients without DLT diarrhea.
(5) Global Phase 1b/2a study(US/EU) planned in 2023.
(6) Exclusive license and distribution agreement for the Korean region has been signed (Korean No. 1 onco-company).
(7) Open for out-licensing or co-development and investment in WW.

[Generic Abraxane ® Update]
(1) Equivalence of physicochemical, pharmacokinetic and anti-tumor effect are confirmed.
(2) Stable scale-up manufacturing process confirmed.
(3) Reliable with simpler manufacturing process with >90% production yields.
(4) Licensing contract for Korean region (Korean No. 1 onco-company)
(5) Open for out-licensing/tech transfer to WW.